Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003953 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00003953 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 39 participants.
The verdict
NCT00003953, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel followed by surgery in treating women who have stage II or stage III breast cancer.
Interventions
- DRUG docetaxel
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG tamoxifen citrate
- DRUG CMF regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1999-02 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003953
The ClinicalTrials.gov registry entry for NCT00003953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT00003953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003953 about?
NCT00003953 is a clinical study titled "Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel followed by surgery in treating women who have stage II or stage III breast cancer.
What is the current status of trial NCT00003953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 1999-02. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00003953?
The interventions under investigation include: docetaxel (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), tamoxifen citrate (DRUG), CMF regimen (DRUG).
Who is sponsoring clinical trial NCT00003953?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.